The Statehouse That Learned to Pick Winners

In the summer of 2026, a company that few Connecticut residents had ever heard of sold to Johnson & Johnson for $3.05 billion. Halda Therapeutics, a New Haven biotech chasing a new class of cancer drugs, had been backed years earlier by an investor most venture capitalists would not recognize either: the government of Connecticut. When the deal closed, the state's own venture fund - Connecticut Innovations - booked one of the largest private biotech exits on record. It was not luck, and it was not the first time.

Connecticut Innovations, known inside the state simply as CI, is the closest thing America has to a permanent, professionally run, government-owned venture capital firm. It was created in 1989 by the Connecticut General Assembly with an unglamorous mandate: keep promising technology and life-science companies from leaving the state, and put public money to work getting them off the ground. Thirty-five years later, it manages named funds, sits on the cap tables of biotech and quantum startups, and answers to taxpayers instead of limited partners.

01 - The ModelA venture firm with a state charter

The idea behind CI is simple to state and hard to execute. Private venture capital tends to cluster where it already exists - Boston, New York, the Bay Area. A founder in New Haven or Hartford with a good molecule or a novel qubit design has historically faced a choice: raise money locally, which was thin, or move to where the money lived. Connecticut decided to build the money locally instead.

CI operates as a quasi-public authority. It invests state capital as equity and convertible debt, from seed rounds through growth stage, and it recycles the returns from exits back into new deals rather than distributing them. That evergreen structure is what lets a government behave like a fund: a good year does not get paid out and forgotten, it becomes next year's dry powder. The organization also administers state incentive programs, most notably an angel investor tax credit that nudges private individuals into early Connecticut deals.

The through-line is founder retention. CI's capital comes with a condition that a private fund would never impose: the company should be based in, or willing to grow in, Connecticut. In exchange, founders get an investor with a long memory, deep local networks, and no pressure to flip a company on a private fund's ten-year clock.

02 - The FundsFour bets, four theses

Rather than run one generalist pool, CI has organized its capital into themed vehicles, each aimed at a sector Connecticut wants to own. The largest is the Connecticut Bioscience Innovation Fund, an evergreen program built to push lab breakthroughs toward commercialization. The newest is the AI/Q Fund, a bet that the state's universities and defense-adjacent engineering base can produce companies at the intersection of artificial intelligence and quantum computing.

The $100 million ClimateTech Fund, launched in 2022 alongside a climate edition of CI's pitch competition, is earmarked for clean energy, low-carbon manufacturing and climate resilience. The $50 million Future Fund exists to back newer ideas and a broader set of founders. Together the named vehicles represent hundreds of millions of dollars in committed public capital, sorted by thesis rather than spread thin.

03 - VentureClashA pitch contest as economic policy

CI's most public-facing product is VentureClash, a global venture competition it launched to surface early-stage companies and, not incidentally, to recruit them. The format is familiar - panels, networking, founders pitching for investment - but the subtext is pure economic development. Winners are offered capital on the condition that they build in Connecticut. A 2022 Climate Edition, run in coordination with the Connecticut Green Bank, tuned the contest toward energy and resilience startups.

It is a clever piece of leverage. Instead of waiting for founders to find the state, CI stages an event that brings founders to it, then uses investment dollars as the closing argument for relocation. Few private funds have any reason to run a recruiting tool like this; for a state investor, it is the whole point.

04 - The Record YearWhat FY2026 actually returned

For most of its life, CI's results were the slow, unshowy kind - a portfolio company acquired here, a modest IPO there. Fiscal 2026 broke the pattern. The fund reported $66.5 million in cash proceeds and $76.1 million combined across all investment activity, its best year on record. The number was driven by two very different exits from two very different funds.

Halda Therapeutics, the New Haven cancer-drug company, was bought by J&J for $3.05 billion in what was described as among the largest private biotech acquisitions on record. Quantum Circuits, a Yale-rooted quantum computing startup, was acquired by D-Wave for $550 million. A third portfolio company, Veradermics, went public on the NYSE, raising $256.3 million. In a single year, CI's biotech, quantum and consumer-health bets all paid out - and, notably, the $59.3 million CI invested during the year pulled in roughly $1.2 billion of outside private capital alongside it.

That multiplier is the real argument for a fund like this. A state that spends $59 million and helps mobilize $1.2 billion in private investment is not running a subsidy program; it is running an anchor investor. The public dollar is not the whole round - it is the signal that makes the rest of the round possible.

05 - The Track RecordAlexion, Biohaven, and the long game

The FY2026 headline exits did not come from nowhere. CI's portfolio over 35 years has produced 13 IPOs and 91 acquisitions, and two of its historical bets became genuine blue-chip drugmakers: Alexion and Biohaven. Both are the kind of company a state points to for a decade. The pattern is consistent - CI tends to be early, patient, and local, and its wins tend to be biotech and deep tech rather than consumer software.

06 - The CompetitionWhere CI sits in the market

CI's real competitors are not other government agencies - they are the private funds in Boston and New York that would happily fund a Connecticut founder and quietly help them relocate. On the public side, it shares a category with programs like MassVentures in Massachusetts and Ben Franklin Technology Partners in Pennsylvania, but CI's scale of named funds and its recent exit record put it near the front of that peer group. It also co-invests with the very private firms it competes against, which is the point: CI wants to be the local anchor that makes an out-of-state syndicate comfortable writing the rest of the check.

Its edge is structural. A private fund optimizes for returns to its limited partners; CI optimizes for returns and jobs and tax base and keeping a founder's next company in Connecticut too. That dual mandate would be a liability if the investing were sloppy. The FY2026 numbers suggest it is not.

07 - What You Can Do With ItIf you are a founder

For an early-stage company in Connecticut, CI is often the first call. It writes seed and growth checks, runs sector-specific funds a founder can apply to directly, hosts VentureClash for companies willing to pitch, and offers technical assistance, talent fairs and introductions across its portfolio. For angel investors, the state's tax credit lowers the cost of backing a young Connecticut business. For the state itself, CI is a way to turn a budget line into a cap-table position - and, in the best years, into a $3 billion exit.

None of this makes government venture capital easy or automatically wise. Public funds can and do lose money, and CI's own returns swing with a small number of large outcomes. But after 35 years, the experiment has a track record most one-off state programs never earn: real exits, real co-investment, and a founder base that increasingly chooses to stay.